The biggest hurdle this week for the SDAHO advocacy team, is SB 154: prohibit pharmaceutical manufacturers from interfering in contracts between 340B entities and pharmacies and to provide a penalty therefor.
This measure will make it so that a pharmaceutical manufacturer cannot directly or indirectly deny, restrict, or prohibit the acquisition of a drug at 340B prices to 340B entities for the use in contract pharmacies.
Changes have been made to the measure through its journey in the legislature. On February 19 It was amended in the Senate Health and Human Services Committee to remove “and the wholesale drug distributors” from the language of the bill. It passed out of committee as amended with a 6-1 vote. It then passed the full Senate as amended 30-2. The measure passed the House Health and Human Services committee earlier this week, with an 8-5 vote. The House of Representatives then went on to pass the measure with a 65-5 vote.
Click here to listen to the audio from the testimony on SB 154 of SDAHO CEO, Tim Rave, and John Ayoub, Mobridge Regional Hospital administrator.
To stay connected with healthcare related legislation, follow our Bill Tracker here.
You can also visit our State Advocacy Webpage.
